Menu
Back to User profile » Dr Toshiharu Yamaguchi
Papers published by Dr Toshiharu Yamaguchi:
Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study
Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Yamaguchi T
Drug Design, Development and Therapy 2015, 9:3099-3108
Published Date: 16 June 2015
Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)
Suenaga M, Fujimoto Y, Matsusaka S, Shinozaki E, Akiyoshi T, Nagayama S, Fukunaga Y, Oya M, Ueno M, Mizunuma N, Yamaguchi T
OncoTargets and Therapy 2015, 8:1111-1118
Published Date: 18 May 2015
Patients’ self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis
Kawakami K, Nakamoto E, Yokokawa T, Sugita K, Mae Y, Hagino A, Suenaga M, Mizunuma N, Oniyama S, Machida Y, Yamaguchi T, Hama T
Patient Preference and Adherence 2015, 9:561-567
Published Date: 9 April 2015
A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Chin K, Yamaguchi T
Drug Design, Development and Therapy 2015, 9:1653-1662
Published Date: 16 March 2015
Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer
Ohhara Y, Suenaga M, Matsusaka S, Shinozaki E, Mizunuma N, Yamaguchi T
OncoTargets and Therapy 2015, 8:529-537
Published Date: 3 March 2015
Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab
Suenaga M, Mizunuma N, Shinozaki E, Matsusaka S, Ozaka M, Ogura M, Chin K, Yamaguchi T
OncoTargets and Therapy 2015, 8:243-249
Published Date: 27 January 2015